TumeyLab

TumeyGroup @binghamtonu, @BingPharmacy, We love science inside the lab and fun outside the lab...

[TumeyLab @TumeyGroup]

https://t.co/d7mKvQvPNw

[TumeyLab @TumeyGroup]

I'm excited to report that our FGFR4-targeting ADC work is now published! This is the most advanced program in development that uses our legumain-cleavable Top1i technology.

[TumeyLab @TumeyGroup]

An exciting month in the Tumey lab! I have an incredible group of students and staff that made this possible - and an amazing department at Binghamton University!
https://t.co/RFe3KYaoG5

[TumeyLab @TumeyGroup]

https://t.co/i2lR91qsFz

[TumeyLab @TumeyGroup]

The adoption of ADC technology outside of oncology will almost certainly require subcutaneous (SQ) administration. In the below article, we describe the current state of the field - describing both the promise and the challenges of developing SQ formulations.

[TumeyLab @TumeyGroup]

https://t.co/1PgEJZRhlJ

[TumeyLab @TumeyGroup]

I’m excited to share our most recent publication describing the development of non-glycosylated (Fc-silent) immune stimulating antibody conjugates (NG-ISACs) for the treatment of TROP2-positive cancers.

[TumeyLab @TumeyGroup]

https://t.co/kKB8WQzNPE

[TumeyLab @TumeyGroup]

Immune-stimulating antibody conjugates (ISACs) are gaining traction! I’m excited to share the full story of our exploration of the role of FcγR’s in the design of TLR7-based ISACs.

[TumeyLab @TumeyGroup]

https://t.co/3L7wYPd4tS

[TumeyLab @TumeyGroup]

I’m excited to share that our legumain-cleavable Top1i paper was just published in J. Med. Chem.!

[TumeyLab @TumeyGroup]

TAF 2024 Award Winner - L. Nathan Tumey - Binghamton University https://t.co/sdc0Vngrn1 via @YouTube

[TumeyLab @TumeyGroup]

Binghamton University is Tackling Childhood Cancer

We are developing a targeted drug delivery system to treat rare childhood cancers—bringing hope for safer, more effective therapies.

[TumeyLab @TumeyGroup]

https://t.co/uuk2qVUmNN

[TumeyLab @TumeyGroup]

https://t.co/dqs8dWUsdw

[Dr. Reddy @DrReddyPhd]

@TumeyGroup reports a native site-specific method to attach drugs at the Q295 site of mabs. Using TPPMS and a resin-supported strategy, they created uniform and stable Antibody-drug Conjugates (ADCs). #bioconjugation, #ADCs, #Cancer https://t.co/G9ZCxyhHb1

[TumeyLab @TumeyGroup]

https://t.co/RG7f5Ejibl

[TumeyLab @TumeyGroup]

🧬 I'm taking part in an NSF I-Corps program to explore market needs for immune-modulating therapies. Looking to speak with 10–15 folks involved in treating autoimmune diseases or developing related drugs. If you're up for a quick 10–15 min chat, DM me or drop a comment. Thanks!

[Dr. Reddy @DrReddyPhd]

@binghamtonu, @BingPharmacy, @TumeyGroup, Researching the researchers: A look into the school of pharmacy’s post-doctoral program https://t.co/jLQQsU7rof

[Dr. Reddy @DrReddyPhd]

#AACR25, Wrapping up after an amazing poster session at #AACR2025 — truly inspiring discussions around #ADCs and #CancerResearch! #AACR2025